Blood Filtration and Purification Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Filtration Kits and Reagents, Membranes, Filters and Consumables, Sample Preparation Systems, Specialty Assays and Columns), By Application (Infectious Disease Diagnostics, Toxicology and Immunodiagnostics, Cancer Diagnostics, Genetic/Molecular Diagnostics, Others), By End User (Clinical Diagnostic Labs, Hospitals, Research and Academic Institutes, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 3.89 Billion
CAGR (2026-2031)	7.34%
Fastest Growing Segment	Genetic/Molecular Diagnostics
Largest Market	North America
Market Size (2031)	USD 5.95 Billion

Market Overview

The Global Blood Filtration and Purification Market will grow from USD 3.89 Billion in 2025 to USD 5.95 Billion by 2031 at a 7.34% CAGR. Blood filtration and purification technologies consist of extracorporeal procedures designed to eliminate metabolic waste, toxins, and pathogens from the circulatory system when renal or hepatic functions are compromised. The growth of this market is primarily anchored by the rising global incidence of chronic kidney disease and the critical demand for sepsis management within intensive care settings. Additionally, the expanding geriatric population, which is highly susceptible to organ failure, provides a foundational driver for these life-sustaining therapies that is distinct from temporary technological shifts or product iterations.

A significant barrier to widespread adoption is the prohibitive cost of long-term treatment and the scarcity of specialized medical personnel in emerging economies. This economic constraint limits market penetration despite the substantial clinical need globally. According to the American Society of Nephrology, in 2025, it was reported that approximately 788 million adults worldwide were living with chronic kidney disease. This statistic underscores the immense disparity between the urgent therapeutic requirement and the financial accessibility of current purification systems.

Key Market Drivers

The escalating global prevalence of Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD) acts as the primary catalyst for market expansion, necessitating continuous renal replacement therapies. This surge is driven by aging populations and the rising incidence of metabolic disorders like diabetes, which accelerate renal decline. The sheer volume of patients requiring life-sustaining filtration creates a non-cyclical demand for hemodialysis and peritoneal dialysis equipment. According to the United States Renal Data System, December 2025, in the '2025 Annual Data Report', 831,192 individuals in the United States were receiving treatment for ESRD at the end of 2023. Such high patient volumes compel healthcare systems to invest heavily in purification infrastructure to manage the growing burden of organ failure.

Technological advancements in portable systems and the increasing adoption of home-based dialysis are fundamentally reshaping service delivery. Providers are prioritizing modalities that offer greater autonomy, moving away from traditional in-center treatments. This shift is supported by innovations in user-friendly devices ensuring safety outside hospitals. According to DaVita Inc., May 2025, in the 'Community Care report', more than 15% of its patients were treated using home-based modalities in 2024. Furthermore, major restructuring reflects this strategic focus; according to Baxter International, in January 2025, the company completed the divestiture of its Kidney Care business for USD 3.8 billion. These developments highlight a market pivot towards accessible purification solutions.

Download Free Sample Report

Key Market Challenges

The prohibitive cost of long-term treatment combined with the scarcity of specialized medical personnel in emerging economies constitutes a formidable barrier to the growth of the Global Blood Filtration and Purification Market. While the rising incidence of organ failure creates an urgent clinical demand, the substantial financial burden associated with these therapies limits their adoption in developing nations. High capital requirements for equipment and the recurring expense of consumables often exceed the healthcare budgets in these regions, effectively severing the link between medical need and market accessibility. Consequently, manufacturers face difficulties in penetrating these high-volume markets where economic constraints override therapeutic requirements.

Furthermore, the deployment of sophisticated purification technologies is directly bottlenecked by a critical shortage of trained practitioners capable of managing extracorporeal procedures. The safe administration of these treatments requires a highly skilled workforce of nephrologists and specialized nurses, which is currently insufficient to meet the expanding patient load. This deficit in human capital hampers the scalability of services, leaving installed capacity underutilized or preventing facility expansion altogether. According to the American Society of Nephrology, in 2025, the sector faced a continued workforce contraction, evidenced by an adult nephrology fellowship fill rate of approximately 73%. This shortfall in the specialist pipeline underscores the depth of the personnel crisis, which stifles the market’s ability to deliver care effectively.

Key Market Trends

The integration of Artificial Intelligence (AI) and Internet of Things (IoT) is transforming the sector by shifting focus from reactive treatment to predictive patient management. Manufacturers are embedding algorithms into dialysis infrastructure to monitor biometrics in real-time and forecast complications before they occur, thereby reducing hospital readmissions. This technological evolution is exemplified by recent clinical innovations presented by major industry players. According to Fresenius Medical Care, October 2025, in a press release regarding 'ASN Kidney Week 2025', the company introduced an AI-driven model capable of predicting fall risks in dialysis patients within a 31-day window, illustrating the tangible application of machine learning in improving clinical safety standards.

Simultaneously, the market is experiencing a significant expansion in the utilization of specialized hemoperfusion and adsorption cartridges for sepsis management. Unlike standard hemodialysis, these purification therapies are specifically engineered to remove inflammatory mediators and cytokines from the blood of critically ill patients, addressing a gap in conventional intensive care protocols. The clinical uptake of these devices has accelerated as healthcare providers seek effective adjunctive therapies for hyperinflammatory conditions. According to CytoSorbents Corporation, September 2025, in a press release detailing its presence at the EACTS Annual Meeting, the company reported that its flagship blood purification technology had been deployed in nearly 300,000 human treatments cumulatively, reflecting the growing reliance on extracorporeal cytokine adsorption globally.

Segmental Insights

The Genetic/Molecular Diagnostics segment is currently the fastest-growing category within the Global Blood Filtration and Purification Market. This rapid expansion is primarily driven by the increasing implementation of personalized medicine, which necessitates highly purified blood samples for accurate genomic analysis. Specialized filtration technologies are essential in this sector to isolate nucleic acids and remove contaminants, such as proteins or inhibitors, that compromise test sensitivity. As clinical laboratories prioritize molecular-based disease detection, the demand for high-performance purification systems that ensure the integrity of genetic material continues to accelerate market development.

Regional Insights

North America maintains a dominant position in the Global Blood Filtration and Purification Market, driven by a highly developed healthcare infrastructure and widespread accessibility to advanced therapeutic procedures. The rising incidence of chronic kidney disease and autoimmune disorders, particularly among the aging population, necessitates frequent hemodialysis and continuous renal replacement therapies. Additionally, the U.S. Food and Drug Administration (FDA) enforces rigorous safety protocols that ensure high device reliability, fostering consistent clinical adoption. This strong regulatory framework, combined with the comprehensive distribution networks of major manufacturers, supports the region's sustained market leadership.

Recent Developments

• In December 2025, Cerus Corporation signed a group purchasing agreement with Blood Centers of America (BCA) to expand the distribution of its pathogen reduction technologies across the United States. The agreement covered the INTERCEPT Blood System for platelets and plasma, as well as the INTERCEPT Fibrinogen Complex, a therapeutic product used to control bleeding. This commercial alliance was designed to facilitate broader adoption of these blood safety measures among BCA’s network of independent blood centers. By increasing access to pathogen-reduced blood components, the collaboration aimed to enhance the security of the blood supply and reduce the risk of transfusion-transmitted infections in the Global Blood Filtration and Purification Market.
• In November 2025, Terumo Blood and Cell Technologies entered into an exclusive strategic collaboration with Santersus AG to advance a novel therapeutic apheresis technology for the treatment of sepsis. The partnership focused on integrating Santersus' NucleoCapture device, which selectively removes neutrophil extracellular traps (NETs) from patient plasma, with Terumo’s Spectra Optia Apheresis System. By targeting these inflammatory drivers, the companies aimed to reduce organ failure and mortality in critically ill patients. This collaboration represented a significant effort to expand the application of blood purification platforms beyond traditional indications into the management of acute systemic inflammation and immune dysregulation.
• In August 2025, Spectral Medical Inc. announced positive topline results from the Phase 3 Tigris trial evaluating the efficacy of the Toraymyxin (PMX) hemoadsorption cartridge for the treatment of endotoxic septic shock. The breakthrough research demonstrated that the device, which removes harmful endotoxins from the bloodstream using polymyxin B-immobilized fibers, provided a statistically significant benefit in reducing mortality among patients with severe sepsis. These findings supported the company’s submission for premarket approval, highlighting the potential of this blood purification technology to improve survival outcomes in critical care settings where standard medical therapies had previously shown limited success.
• In February 2024, Fresenius Medical Care received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the 5008X Hemodialysis System, a device designed to enable high-volume hemodiafiltration (Hv-HDF). This regulatory approval marked a significant development in the blood purification market, as it allowed the company to introduce a therapy that combines diffusion and convection to remove larger waste molecules from the blood more effectively than standard hemodialysis. The clearance paved the way for clinical evaluations and a subsequent commercial rollout in the United States, aiming to establish Hv-HDF as a new standard of care for patients with kidney failure.

Key Market Players

• Fresenius Medical Care AG & Co. KGaA
• Baxter International Inc.
• B. Braun Melsungen AG
• Nikkiso Co., Ltd.
• Terumo Corporation
• Asahi Kasei Medical Co., Ltd.
• Kawasumi Laboratories, Inc.
• Medtronic plc
• Toray Medical Co., Ltd.
• Jafron Biomedical Co., Ltd.

By Product	By Application	By End User	By Region
Filtration Kits and Reagents Membranes Filters and Consumables Sample Preparation Systems Specialty Assays and Columns	Infectious Disease Diagnostics Toxicology and Immunodiagnostics Cancer Diagnostics Genetic/Molecular Diagnostics Others	Clinical Diagnostic Labs Hospitals Research and Academic Institutes Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Blood Filtration and Purification Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Blood Filtration and Purification Market, By Product:

• Filtration Kits and Reagents
• Membranes
• Filters and Consumables
• Sample Preparation Systems
• Specialty Assays and Columns

• Blood Filtration and Purification Market, By Application:

• Infectious Disease Diagnostics
• Toxicology and Immunodiagnostics
• Cancer Diagnostics
• Genetic/Molecular Diagnostics
• Others

• Blood Filtration and Purification Market, By End User:

• Clinical Diagnostic Labs
• Hospitals
• Research and Academic Institutes
• Others

• Blood Filtration and Purification Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE